Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.
about
Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients.Activating HER3 mutations in breast cancer.US-guided Diffuse Optical Tomography: Clinicopathological Features Affect Total Hemoglobin Concentration in Breast CancerClinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancerEstradiol promotes rapid degradation of HER3 in ER-positive breast cancer cell line MCF-7
P2860
Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.
description
2017 nî lūn-bûn
@nan
2017 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Direct estrogen receptor (ER) ...... rtuzumab in ER+ breast cancer.
@ast
Direct estrogen receptor (ER) ...... rtuzumab in ER+ breast cancer.
@en
type
label
Direct estrogen receptor (ER) ...... rtuzumab in ER+ breast cancer.
@ast
Direct estrogen receptor (ER) ...... rtuzumab in ER+ breast cancer.
@en
prefLabel
Direct estrogen receptor (ER) ...... rtuzumab in ER+ breast cancer.
@ast
Direct estrogen receptor (ER) ...... rtuzumab in ER+ breast cancer.
@en
P2093
P2860
P1433
P1476
Direct estrogen receptor (ER) ...... ertuzumab in ER+ breast cancer
@en
P2093
Andrés Cervantes
John Crown
Juan Miguel Cejalvo
Martin Weisser
Maurizio Ceppi
Max Hasmann
Wolfgang Jacob
P2860
P304
P356
10.1371/JOURNAL.PONE.0177331
P407
P577
2017-05-11T00:00:00Z